Trials / Completed
CompletedNCT04332432
A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Galectin Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
This study will assess the pharmacokinetics of belapectin in subjects with mild, moderate, or severe hepatic impairment according to 3 different Child-Pugh categories: mild, moderate, or severe impairment, compared to matched healthy control subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | belapectin | intravenous |
Timeline
- Start date
- 2020-06-16
- Primary completion
- 2022-03-09
- Completion
- 2022-03-09
- First posted
- 2020-04-02
- Last updated
- 2022-03-28
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04332432. Inclusion in this directory is not an endorsement.